Hispanic, Indigenous Americans Undercaptured in National Cancer Database
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Dec. 27, 2023 -- Hispanic and American Indian or Alaska Native (AI/AN) individuals diagnosed with breast, colorectal, lung, and prostate cancer have been undercaptured in the National Cancer Database (NCDB), but their representation is improving, according to a study published online Dec. 27 in JAMA Network Open.
Yasoda Satpathy, from the University of California San Diego School of Medicine in La Jolla, and colleagues conducted a multicenter, retrospective cohort study to examine representation of Hispanic and AI/AN individuals in the NCDB compared to the U.S. Cancer Statistics (USCS) database. The absolute percentage change (APC) in capture rates was examined across the study period.
The cohort included 5,175,007 individuals (0.50, 3.10, 12.01, 6.58, and 77.81 percent AI/AN, Asian or Pacific Islander, Black, Hispanic, and White, respectively) diagnosed with breast, colorectal, lung, or prostate cancer. The researchers found that in 2004 to 2006 and 2017 to 2019, capture rates were lowest for individuals who were Hispanic (40.83 and 54.75 percent, respectively) or AI/AN (20.72 and 41.41 percent, respectively). Across all four cancers, APCs were positive for both racial categories. For AI/AN individuals, the APCs were greater than for White individuals for prostate (14.68 versus 11.57 percent) and breast (21.61 versus 17.90 percent) cancer, while for lung cancer, APCs were lower (24.54 versus 33.03 percent).
"These findings indicate that Hispanic and AI/AN representation has increased over time, but further efforts are needed," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted December 2023
Read this next
ACG: 2000 to 2022 Saw Rise in Early-Onset CRC Mortality in the United States
THURSDAY, Oct. 31, 2024 -- Early-onset colorectal cancer (EO-CRC) mortality rose in the United States over the past two decades, most notably in patients aged 20 to 44 years...
Cell-Free Blood DNA Tests Less Effective Than Other CRC Screening
WEDNESDAY, Oct. 30, 2024 -- Cell-free DNA blood tests (cf-bDNA) may be more costly and less effective for colorectal cancer (CRC) screening than other screening modalities...
American College of Surgeons, Oct. 19-22
The annual meeting of the American College of Surgeons was held this year from Oct. 19 to 22 in San Francisco and attracted participants from around the world, including...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.